The reduction in NO bioavailability was accompanied by a significant decrease in sGC activity, reduced cGMP levels, and subsequently a significant reduction in PKG activity observed in HFpEF DM patients compared to HFpEF non-DM patients (Fig. 3E, F, G). The gene discussed is SGCB; the disease is diabetes mellitus.